Tech Company Financing Transactions
Anoat Therapeutics Funding Round
Anoat Therapeutics, based in Paris, secured $2.2 million in funding from AdBio Partners.
Transaction Overview
Company Name
Announced On
6/19/2023
Transaction Type
Venture Equity
Amount
$2,186,000
Round
Seed
Investors
AdBio Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4 rue Thénard
Paris, 75005
FR
Paris, 75005
FR
Phone
Website
Email Address
Overview
AdBio partners (formerly Advent France Biotechnology) is a venture capital firm investing in early stage life sciences companies in Europe. AdBio partners' unique strategy combines early-stage investments in promising startups and strong entrepreneurial support to enable and strengthen the company's growth.As an early-stage investor, we act as a catalyst to create companies based on innovations coming from academic research. We have established relationships with leading research institutions and technology transfer offices in Europe and benefit from the support of strong network of scientific, clinical, industry and financial partners.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Alain HURIEZ
Chief Financial Officer
Sidonie FABRE
Co-Founder
Matthieu COUTET
Co-Founder
Geoffroy RIBAINS
Browse more venture capital transactions:
Prev: 6/19/2023: GlassDollar venture capital transaction
Next: 6/19/2023: Deeploy venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs